Immunic, Inc. (IMUX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Immunic, Inc. (IMUX) is up 176.4% since the beginning of the year. At $15 per share, IMUX is trading 6.5% below its 52-week high of $16. Investors who bought $1,000 worth of IMUX shares 5 years ago would now be looking at an investment worth $122.

Immunic, Inc. (IMUX) has returned 176.37% so far this year and 104.86% over the past 12 months. Over the last ten years, IMUX has returned -40.43% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Apr 17, 2014, IMUX's average daily return is +0.12%, while the average monthly return is +1.04%. At this rate, an investment would double in approximately 5.6 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jun 2014 with a return of +127.0%, while the worst month was Sep 2018 at -96.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, IMUX closed higher 47% of trading days. The best single day was Apr 5, 2019 with a return of +145.9%, while the worst single day was Sep 12, 2018 at -92.9%.

Immunic, Inc. has an annualized alpha of 13.88%, beta of 1.23, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 17, 2014.

• This stock participated in 208.16% of S&P 500 Index downside but only -9.53% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMUX ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immunic, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunic, Inc. was 99.96%, occurring on Dec 30, 2025. The portfolio has not yet recovered.

The current Immunic, Inc. drawdown is 99.89%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immunic, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immunic, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.